Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Amlodipine besylate valsartan hydrochlorothiazide

Drug class: Angiotensin 2 Receptor Blocker, Thiazide Diuretic

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Amlodipine besylate valsartan hydrochlorothiazide key facts

Drug class
Angiotensin 2 Receptor Blocker
Used for
Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$5.00 per tablet (amlodipine besylate 10 mg · hydrochlorothiazide 12.5 mg · valsartan 160 mg; NADAC)
Latest FDA recall
None listed

Sources: FDA label (October 28, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Amlodipine besylate valsartan hydrochlorothiazide used for?
The FDA-approved label (Exforge HCT, Novartis Pharmaceuticals Corporation, October 28, 2026) says: “Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Amlodipine besylate valsartan hydrochlorothiazide?
The “Adverse Reactions” section of the FDA label (Exforge HCT, Novartis Pharmaceuticals Corporation, October 28, 2026) begins: “Most common adverse events (≥ 2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea, and nasopharyngitis.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Amlodipine besylate valsartan hydrochlorothiazide?
The “Drug Interactions” section of the FDA label (Exforge HCT, Novartis Pharmaceuticals Corporation, October 28, 2026) begins: “No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Amlodipine besylate valsartan hydrochlorothiazide have a boxed warning?
Yes. The FDA label for Exforge HCT has a boxed warning (“WARNING: FETAL TOXICITY”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Amlodipine besylate valsartan hydrochlorothiazide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Amlodipine besylate valsartan hydrochlorothiazide been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Amlodipine besylate valsartan hydrochlorothiazide?
6 companies list prescription products of Amlodipine besylate valsartan hydrochlorothiazide in the FDA NDC Directory, including Golden State Medical Supply, Inc., Strides Pharma Science Limited and Macleods Pharmaceuticals Limited.

What Amlodipine besylate valsartan hydrochlorothiazide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. …

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, film coated, oral), Exforge HCT, Novartis Pharmaceuticals Corporation; it covers 5 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 6 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Its heading: WARNING: FETAL TOXICITY. Read it on the full label →

6 of 6 FDA labels for this medicine have a boxed warning.

Amlodipine besylate valsartan hydrochlorothiazide boxed warning: what the label says

Quoted from the boxed warning of the FDA-approved label.

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Exforge HCT as soon as possible.

Read more of this section

(5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. Read the full label on DailyMed →

Amlodipine besylate valsartan hydrochlorothiazide side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

Most common adverse events (≥ 2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea, and nasopharyngitis.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. In the controlled trial of Exforge HCT, where only the maximum dose (10/320/25 mg) was evaluated, safety data were obtained in 582 patients with hypertension. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall frequency of adverse reactions was similar between men and women, younger (< 65 years) and older (> 65 years) patients, and black and white patients. In the active controlled clinical trial, discontinuation because of adverse events occurred in 4.0% of patients treated with Exforge HCT 10/320/25 mg compared to 2.9% of patients treated with valsartan/HCTZ 320/25 mg, 1.6% of patients treated with amlodipine/valsartan 10/320 mg, and 3.4% of patients treated with HCTZ/amlodipine 25/10 mg. The most common reasons for discontinuation of therapy with Exforge HCT were dizziness (1.0%) and hypotension (0.7%). The most frequent adverse events that occurred in the active controlled clinical trial in at least 2% of patients treated with Exforge HCT are presented in the following table. Preferred Term Aml/Val/HCTZ 10/320/25 mg N=582 n (%) Val/HCTZ 320/25 mg N=559 n (%) Aml/Val 10/320 mg N=566 n (%) HCTZ/Aml 25/10 mg N=561 n (%) Dizziness 48 (8.2) 40 (7.2) 14 (2.5) 23 (4.1) Edema 38 (6.5) 8 (1.4) 65 (11.5) 63 (11.2) Headache 30 (5.2) 31 (5.5) 30 (5.3) 40 (7.1) Dyspepsia 13 (2.2) 5 (0.9) 6 (1.1) 2 (0.4) Fatigue 13 (2.2) 15 (2.7) 12 (2.1) 8 (1.4) Muscle spasms 13 (2.2) 7 (1.3) 7 (1.2) 5 (0.9) Back pain 12 (2.1) 13 (2.3) 5 (0.9) 12 (2.1) Nausea 12 (2.1) 7 (1.3) 10 (1.8) 12 (2.1) Nasopharyngitis 12 (2.1) 13 (2.3) 13 (2.3) 12 (2.1) Orthostatic events (orthostatic hypotension and postural dizziness) were seen in 0.5% of patients. Valsartan Valsartan has been evaluated for safety in more than 4000 hypertensive patients in clinical trials. In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of dry cough was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had dry cough when they had previously received ACE inhibitors, the incidences of cough in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69%, respectively (p < 0.001).

Table from the label
Preferred TermAml/Val/HCTZ 10/320/25 mg N=582 n (%)Val/HCTZ 320/25 mg N=559 n (%)Aml/Val 10/320 mg N=566 n (%)HCTZ/Aml 25/10 mg N=561 n (%)
Dizziness48 (8.2)40 (7.2)14 (2.5)23 (4.1)
Edema38 (6.5)8 (1.4)65 (11.5 )63 (11.2)
Headache30 (5.2)31 (5.5)30 (5.3)40 (7.1)
Dyspepsia13 (2.2)5 (0.9)6 (1.1)2 (0.4)
Fatigue13 (2.2)15 (2.7)12 (2.1)8 (1.4)
Muscle spasms13 (2.2)7 (1.3)7 (1.2)5 (0.9)
Back pain12 (2.1)13 (2.3)5 (0.9)12 (2.1)
Nausea12 (2.1)7 (1.3)10 (1.8)12 (2.1)
Nasopharyngitis12 (2.1)13 (2.3)13 (2.3)12 (2.1)

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. This is part of the section. Read the full label on DailyMed →

Amlodipine besylate valsartan hydrochlorothiazide drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed.

Read more of this section

Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment [see Clinical Pharmacology (12.3)]. CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g., rifampicin, St. John’s Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine [see Clinical Pharmacology (12.2)]. Impact of Amlodipine on Other Drugs Simvastatin Coadministration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily [see Clinical Pharmacology (12.3)]. Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3)]. Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine. If co-medication is considered necessary, monitoring of serum potassium is advisable. Non-Steroidal Anti-Inflammatory (NSAID) Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving valsartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including valsartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. This is part of the section. Read the full label on DailyMed →

Amlodipine besylate valsartan hydrochlorothiazide dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Dose once-daily. Titrate up to a maximum dose of 10/320/25 mg. (2.1) Exforge HCT may be used as add-on/switch therapy for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics. (2.2) Exforge HCT may be substituted for its individually titrated components. (2.3) 2.1 General Considerations Dose once-daily. The dosage may be increased after 2 weeks of therapy.

Read more of this section

The full blood pressure lowering effect was achieved 2 weeks after being on the maximal dose of Exforge HCT. The maximum recommended dose of Exforge HCT is 10/320/25 mg. 2.2 Add-on/Switch Therapy Exforge HCT may be used for patients not adequately controlled on any 2 of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics. A patient who experiences dose-limiting adverse reactions to an individual component while on any dual combination of the components of Exforge HCT may be switched to Exforge HCT containing a lower dose of that component to achieve similar blood pressure reductions. 2.3 Replacement Therapy Exforge HCT may be substituted for the individually titrated components. 2.4 Use With Other Antihypertensive Drugs Exforge HCT may be administered with other antihypertensive agents.

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. Read the full label on DailyMed →

Amlodipine besylate valsartan hydrochlorothiazide in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Exforge HCT can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.

Read more of this section

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Published reports include cases of anhydramnios and oligohydramnios in pregnant women treated with valsartan (see Clinical Considerations). When pregnancy is detected, discontinue Exforge HCT as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Valsartan Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of gestation. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. If oligohydramnios is observed, consider alternative drug treatment. Closely observe neonates with histories of in utero exposure to Exforge HCT for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to Exforge HCT, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. Hydrochlorothiazide Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma. Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. It accumulates in the amniotic fluid, with reported concentrations up to 19 times higher than in umbilical vein plasma.

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. This is part of the section. Read the full label on DailyMed →

When Amlodipine besylate valsartan hydrochlorothiazide should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Do not use in patients with anuria, hypersensitivity to other sulfonamide-derived drugs, or hypersensitivity to any component of this product. Do not coadminister aliskiren with Exforge HCT in patients with diabetes [see Drug Interactions (7)]. Anuria (4) Hypersensitivity to sulfonamide-derived drugs (4) Known hypersensitivity to any component (4) Do not coadminister aliskiren with Exforge HCT in patients with diabetes (4)

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. Read the full label on DailyMed →

Amlodipine besylate valsartan hydrochlorothiazide overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, institute supportive treatment. Amlodipine Single oral doses of amlodipine maleate equivalent to 40 mg/kg and 100 mg/kg amlodipine in mice and rats, respectively, caused deaths.

Read more of this section

Single oral doses equivalent to 4 or more mg/kg amlodipine in dogs (11 or more times the MRHD on a mg/m 2 basis) caused a marked peripheral vasodilation and hypotension. Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension. In humans, experience with intentional overdosage of amlodipine is limited. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported. If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should hypotension occur, initiate cardiovascular support, including elevation of the extremities and the judicious administration of fluids. If hypotension remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Valsartan Depressed level of consciousness, circulatory collapse, and shock have been reported. Valsartan is not removed from the plasma by hemodialysis. Valsartan was without grossly observable adverse effects at single oral doses up to 2,000 mg/kg in rats and up to 1,000 mg/kg in marmosets, except for salivation and diarrhea in the rat and vomiting in the marmoset at the highest dose (60 and 31 times, respectively, the MRHD on a mg/m 2 basis) (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Hydrochlorothiazide The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The most common signs and symptoms observed in patients are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD 50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats, 2000 and 4000 times, respectively, the MRHD on a mg/m 2 basis (calculations assume an oral dose of 25 mg/day and a 60-kg patient). Valsartan and Hydrochlorothiazide In rats and marmosets, single oral doses of valsartan up to 1524 and 762 mg/kg in combination with hydrochlorothiazide at doses up to 476 and 238 mg/kg, respectively, were very well tolerated without any treatment-related effects.

— FDA label: Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026. This is part of the section. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet, film coated
RouteOral
Prescription products30 in the FDA NDC Directory
Brand namesExforge Hct

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Amlodipine besylate valsartan hydrochlorothiazide, by strength and form
Strength and formGeneric or brandPharmacies pay
amlodipine besylate 10 mg · hydrochlorothiazide 12.5 mg · valsartan 160 mg
tablet, film coated
Generic $5.00 per tablet
amlodipine besylate 10 mg · hydrochlorothiazide 25 mg · valsartan 160 mg
tablet, film coated
Generic $6.11 per tablet
amlodipine besylate 10 mg · hydrochlorothiazide 25 mg · valsartan 320 mg
tablet, film coated
Generic $5.85 per tablet
amlodipine besylate 10 mg · hydrochlorothiazide 25 mg · valsartan 320 mg
tablet, film coated
Brand: Exforge HCT $15.45 per tablet
amlodipine besylate 5 mg · hydrochlorothiazide 12.5 mg · valsartan 160 mg
tablet, film coated
Generic $4.66 per tablet
amlodipine besylate 5 mg · hydrochlorothiazide 25 mg · valsartan 160 mg
tablet, film coated
Generic $4.17 per tablet

NADAC list of November 11, 2026; these prices took effect between January 7, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA022314
EXFORGE HCT
NovartisApril 30, 2009 17, latest September 26, 2022
2022: Manufacturing (CMC) · 2021: Labeling · 2020: Labeling

Generic approvals (4)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)848131, 848134, 848135, 848139, 848140, 848144, 848145, 848149, 848151, 848155
SPL set ID of the quoted label18d7820d-471f-4ee2-9ec6-25d8d27c77de
FDA labels (SPL)6
FDA applicationsNDA022314, 4 ANDA
Active ingredients (FDA)AMLODIPINE / HYDROCHLOROTHIAZIDE / VALSARTAN

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Exforge HCT, Novartis Pharmaceuticals Corporation, effective October 28, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers